

07 Aug 2019 | News

QUOTED. 7 August 2019. Andrew Newland.

by

UK-based liquid biopsy company Angle PLC is expecting to make a landmark regulatory submission to the US Food and Drug Administration early in the fourth quarter of 2019 for Parsortix, which aims to detect and capture circulating tumor cells in cancer patients. See what Angle's CEO, Andrew Newland, said about it here.

"What we're focused on with metastatic breast cancer and ovarian cancer is really just the tip of the iceberg," Newland said. "They're the examples we are using to prove to the market, but there are all these other cancer types that can be developed once we have those in place." – Andrew Newland, CEO, Angle

- Find out more: [Angle Edges Closer To US FDA Clearance For Liquid Biopsy System](#)

[Click here](#) for a free trial of *Medtech Insight*